سعر ساكسندا 18 مجم/ 3 مل 3 أقلام معبأة للحقن تحت الجلد 6 مجم/مل 2026

Liraglutide 6 mg/ml (18 mg/3 ml) solution in a pre-filled pen for once-daily subcutaneous injection (Novo Nordisk), used for chronic weight management.

• Adjunct to a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight plus at least one weight-related comorbidity, and in paediatric patients aged 12 years and older with body weight above 60 kg and obesity.Population: Adults and paediatric patients >=12 yearsDailyMed (U.S. National Library of Medicine)

• Most common (>=5%): nausea, diarrhoea, constipation, vomiting, injection-site reactions, headache, hypoglycaemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia and gastroenteritis.International label, same product · DailyMed (U.S. National Library of Medicine)

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).International label, same product · DailyMed (U.S. National Library of Medicine)
• Serious hypersensitivity to liraglutide or any excipient (anaphylaxis and angioedema have been reported).International label, same product · DailyMed (U.S. National Library of Medicine)

• Boxed warning: liraglutide causes thyroid C-cell tumours in rodents; human relevance unknown; counsel patients on symptoms of thyroid tumours (neck mass, dysphagia, dyspnoea, persistent hoarseness).International label, same product · DailyMed (U.S. National Library of Medicine)
• Acute pancreatitis (including haemorrhagic or necrotising) has occurred; discontinue if suspected.International label, same product · DailyMed (U.S. National Library of Medicine)
• Acute gallbladder disease (cholelithiasis, cholecystitis) occurred more often than with placebo.International label, same product · DailyMed (U.S. National Library of Medicine)

• Oral medicationsDelayed gastric emptying may affect absorption of oral drugs; monitor for consequences of delayed absorption.DailyMed (U.S. National Library of Medicine)
• Insulin and insulin secretagogues (e.g. sulfonylureas)Increased risk of hypoglycaemia; a dose reduction of the insulin or secretagogue may be needed.DailyMed (U.S. National Library of Medicine)
• Other liraglutide-containing products or other GLP-1 receptor agonistsCoadministration is not recommended.DailyMed (U.S. National Library of Medicine)

• Animal studies suggest possible fetal risk and weight loss offers no benefit in pregnancy; discontinue Saxenda when pregnancy is recognised.International label, same product · DailyMed (U.S. National Library of Medicine)
• No data on liraglutide in human milk or effects on the breastfed infant; liraglutide is present in rat milk; weigh benefits of breastfeeding against the mother's need.International label, same product · DailyMed (U.S. National Library of Medicine)

• Liraglutide: Acylated human GLP-1 receptor agonist (97% homology to native GLP-1); lowers body weight through decreased calorie intake and delays gastric emptying (US label 12.1-12.2).